The global varicose vein treatment market size was valued at USD 1.74 billion in 2025 and is projected to grow from USD 1.85 billion in 2026 to USD 2.95 billion by 2034, registering a CAGR of 6.05% during the forecast period from 2026 to 2034. North America dominated the varicose vein treatment market with a market share of 38.6% in 2025.
Varicose vein treatment refers to medical procedures and therapies used to manage enlarged, twisted veins caused by weakened or damaged vein valves, most commonly in the legs. Treatment options include compression therapy, sclerotherapy, endovenous laser therapy (EVLT), radiofrequency ablation (RFA), vein stripping, and minimally invasive procedures. The growing prevalence of venous disorders, aging populations, and increasing preference for minimally invasive treatments are driving the growth of the varicose vein treatment market.
Download a Free Sample To learn more about this report,
Growing Shift Toward Nonthermal Endovenous Treatment Technologies
The varicose vein treatment market is moving beyond conventional thermal ablation toward nonthermal approaches that can close diseased veins without delivering thermal energy to surrounding tissue. These techniques are expanding treatment choices for patients and physicians by offering alternative procedural approaches that may reduce dependence on tumescent anesthesia and heat-based treatment.
Increasing Development of More Targeted Endovenous Ablation Techniques
Treatment technologies are increasingly being refined to improve the precision of vein closure while addressing multiple diseased venous segments within minimally invasive procedures. This is encouraging the development of techniques designed to treat truncal veins, tributaries, and perforators with greater procedural control.
Increasing Diagnosis of Symptomatic Venous Reflux Expands Treatment Demand
Greater clinical identification of venous reflux is supporting demand for interventions that restore normal venous blood flow and relieve symptoms such as pain, swelling, heaviness, and discomfort. Duplex ultrasound assessment helps clinicians identify the extent of reflux and determine appropriate treatment, creating a pathway from diagnosis to intervention.
Recurrence of Venous Disease Can Require Additional Treatment Sessions
Varicose vein treatment does not eliminate the possibility of future venous reflux or development of additional varicosities. The potential need for retreatment can increase the overall treatment burden for patients and healthcare providers, particularly when disease involves multiple venous segments.
Expansion of Same-Day Minimally Invasive Venous Procedures Creates New Service Opportunities
Healthcare providers are increasingly seeking procedural approaches that can shorten recovery and reduce the burden associated with conventional surgical treatment. Technologies that enable minimally invasive treatment with efficient post-procedure recovery can therefore support expansion of outpatient venous-care services.
Demonstrating Long-Term Durability Across Emerging Treatment Modalities Remains Difficult
New ablation technologies must demonstrate sustained vein closure, symptom improvement, and acceptable complication rates over extended follow-up. Differences in anatomy, disease severity, procedural technique, and treatment modality can make it difficult to establish long-term comparative performance across competing interventions.
Endovenous Ablation Segment Dominated the Market with 43.5% Share in 2025
The endovenous ablation segment dominated the varicose vein treatment market with a 43.5% market share in 2025, accounting for USD 0.76 billion, and is projected to grow at a CAGR of 7.24% during the forecast period. The segment's dominance is driven by the increasing preference for minimally invasive procedures that offer faster recovery, reduced pain, and improved clinical outcomes compared with conventional surgery. Rising adoption of laser and radiofrequency ablation technologies continues to strengthen the segment's leading position.
The sclerotherapy, ligation, and supportive treatments segments also contribute significantly to the varicose vein treatment market. Sclerotherapy remains widely used for treating smaller varicose and spider veins, while ligation and supportive therapies continue to play an important role in managing chronic venous disorders and improving patient outcomes.
Request Customizationto receive a tailored report.
Laser Ablation Devices Segment is Projected to Register the Fastest Growth at a CAGR of 7.55%
The laser ablation devices segment is projected to register the fastest CAGR of 7.55% during 2026–2034. The segment accounted for 17.2% of the market, valued at USD 0.30 billion in 2025. Growth is driven by increasing adoption of minimally invasive laser-based procedures that provide high treatment precision, shorter recovery periods, and lower complication rates. Continuous technological advancements in laser systems and growing patient preference for outpatient procedures are further supporting segment expansion.
The ablation devices, radio frequency ablation or thermal ablation, ultrasound ablation devices, catheters or kits for sclerotherapy & adhesion injections, compression devices, and others segments continue to contribute significantly to the varicose vein treatment market. Growing demand for advanced treatment technologies and improved procedural efficiency continues to support adoption across these product categories.
Hospitals Segment Dominated the Market with 46.7% Share in 2025
The hospitals segment dominated the varicose vein treatment market with a 46.7% market share in 2025, accounting for USD 0.81 billion, and is projected to grow at a CAGR of 6.42% during the forecast period. The segment's leadership is attributed to the availability of advanced vascular treatment technologies, experienced healthcare professionals, and comprehensive diagnostic and post-treatment care. Increasing patient preference for hospital-based minimally invasive procedures continues to strengthen the segment's market position.
The ambulatory surgical centers, specialty clinics, and others segments also contribute significantly to the varicose vein treatment market. Ambulatory surgical centers are witnessing increasing adoption due to cost-effective outpatient procedures, while specialty clinics continue to expand because of their focused expertise in venous disease diagnosis and treatment.
Speak to an Analystto discuss market opportunities.
North America dominated the varicose vein treatment market with a 38.6% share in 2025, accounting for USD 0.67 billion, and is projected to grow at a CAGR of 6.35% during the forecast period. Growth is driven by the high prevalence of chronic venous disorders, increasing adoption of minimally invasive treatment procedures, advanced healthcare infrastructure, and growing awareness of vascular health. The presence of leading medical device manufacturers and favorable reimbursement policies further support regional market growth.
The U.S. market was valued at USD 0.57 billion in 2025, making it the largest contributor in North America. Rising demand for endovenous ablation procedures, increasing obesity rates, growing aging population, and widespread availability of advanced vascular treatment technologies continue to drive market growth.
Canada's market reached USD 0.10 billion in 2025. Increasing awareness of chronic venous disease, expanding access to minimally invasive procedures, improving healthcare infrastructure, and rising adoption of laser and radiofrequency ablation technologies continue to support steady market expansion.
Unlock Regional Insightsto access country-level data, & regional trends.
Europe accounted for 29.4% of the varicose vein treatment market, reaching USD 0.51 billion in 2025, and is expected to register a CAGR of 6.18% during the forecast period. Increasing prevalence of venous disorders, growing elderly population, favorable healthcare reimbursement, and rising adoption of advanced endovenous treatment technologies continue to drive regional market growth.
The U.K. market was valued at USD 0.12 billion in 2025. Rising awareness of minimally invasive vein treatments, increasing outpatient procedures, and expanding vascular healthcare services continue to support market growth.
Germany's market accounted for USD 0.15 billion in 2025. Strong healthcare infrastructure, increasing adoption of advanced vein treatment devices, and growing demand for minimally invasive vascular procedures continue to support market expansion.
Asia Pacific held 21.8% of the varicose vein treatment market, valued at USD 0.38 billion in 2025, and is projected to register the fastest CAGR of 7.84% during the forecast period. Rising healthcare expenditure, increasing awareness of venous disorders, growing medical tourism, and expanding access to advanced vascular treatment technologies are driving regional market growth.
Japan's market generated USD 0.09 billion in 2025. The country's aging population, increasing prevalence of chronic venous diseases, and growing adoption of minimally invasive treatment procedures continue to support market growth.
China's market accounted for USD 0.20 billion in 2025, representing the largest share within Asia Pacific. Rapid healthcare infrastructure development, increasing patient awareness, expanding availability of advanced vein treatment technologies, and growing investments in vascular care continue to drive market expansion.
Middle East & Africa accounted for 4.1% of the varicose vein treatment market, totaling USD 0.07 billion in 2025, and is anticipated to grow at a CAGR of 6.29% during the forecast period. Increasing healthcare investments, rising prevalence of lifestyle-related vascular disorders, improving access to minimally invasive treatments, and expanding specialty vascular clinics continue to support regional market growth.
The UAE market was valued at USD 0.02 billion in 2025. Rising investments in advanced healthcare infrastructure, increasing medical tourism, and growing adoption of minimally invasive vein treatment procedures continue to drive market growth.
Africa's market reached USD 0.05 billion in 2025. Improving healthcare access, increasing awareness of venous disorders, expanding vascular treatment services, and rising investments in healthcare infrastructure continue to create long-term growth opportunities across the region.
Customize This Report to Match Your Strategic Objectives
Author's Details
Senior Research Associate
Dhanshee Bhapkar is a healthcare research professional with 4+ years of experience in market intelligence, specializing in market analysis, secondary research, market estimation, and forecasting across the pharmaceutical, biopharmaceutical, and medical device sectors. She provides actionable insights into market dynamics, competitive intelligence, industry trends, and growth opportunities to support strategic business decision-making.
Her expertise includes assessing market size, growth potential, and revenue opportunities through structured market estimation and forecasting methodologies, including top-down, bottom-up, and epidemiology (EPI)-based approaches. She has hands-on experience analyzing disease epidemiology, treatment landscapes, market trends, competitive scenarios, and industry developments to develop robust market forecasts.
Precision Cardiology Market Size, Share, Growth, Analysis, 2034
Europe Aesthetic Medicine Market Size, Top Share, Forecast ,2034
Latin America Neurodegenerative Diseases Market Includes Latest Trends, 2034
Asia Pacific Neurodegenerative Diseases Market Size, Share by 2034
LAMEA Lidocaine Market Size, Growth , 2026-2034
North America Neurodegenerative Disease Market Size, 2034
We are featured on:
sales@straitsresearch.com